Association of Liver Fat Fraction Assessed by MRI IDEAL-IQ with ALT, GGT, and AST Levels in Colorectal Cancer Patients Post-Chemotherapy - Report - MDSpire
Advertisement
Association of Liver Fat Fraction Assessed by MRI IDEAL-IQ with ALT, GGT, and AST Levels in Colorectal Cancer Patients Post-Chemotherapy
Association of Liver Fat Fraction Assessed by MRI IDEAL-IQ with ALT, GGT, and AST Levels in Colorectal Cancer Patients Post-Chemotherapy
Overview
This study investigates the correlation between hepatic fat fraction (HFF) measured by MRI IDEAL-IQ and serum liver enzymes (ALT, GGT, AST) in colorectal cancer patients undergoing FOLFOX4 chemotherapy. The findings suggest that MRI can serve as a reliable non-invasive method for monitoring chemotherapy-induced hepatic steatosis.
Background
Chemotherapy-induced liver injury, particularly hepatic steatosis, is a significant concern in colorectal cancer management, affecting patient outcomes and treatment strategies. Traditional serum enzyme markers are insufficient for accurately assessing liver fat content, highlighting the need for non-invasive imaging techniques. The IDEAL-IQ MRI technique offers a promising solution for quantifying hepatic fat fraction, potentially improving clinical decision-making.
Data Highlights
No numerical data available in the provided source.
Key Findings
56 colorectal cancer patients receiving FOLFOX4 chemotherapy were analyzed.
60 control patients who did not receive chemotherapy were included for comparison.
IDEAL-IQ MRI demonstrated high accuracy in quantifying hepatic fat fraction.
Correlations between HFF and serum liver enzymes (ALT, GGT, AST) were assessed.
The study emphasizes the importance of non-invasive imaging in monitoring liver health during chemotherapy.
Clinical Implications
The use of IDEAL-IQ MRI for assessing hepatic fat fraction can enhance the monitoring of liver health in colorectal cancer patients undergoing chemotherapy. This non-invasive approach may help prevent misdiagnosis and guide treatment strategies more effectively.
Conclusion
The study supports the feasibility of using MRI IDEAL-IQ as a non-invasive tool for evaluating hepatic steatosis in colorectal cancer patients post-chemotherapy, potentially improving patient management and outcomes.
